DAGLβ Inhibitors

DAGLβ inhibitors are a class of chemicals that directly or indirectly reduce the activity of diacylglycerol lipase beta, an enzyme critical for the production of the endocannabinoid 2-arachidonoylglycerol (2-AG). These inhibitors accomplish their function through several mechanisms, including competitive inhibition, where the inhibitor molecules compete with the natural substrate (diacylglycerol) for binding to the active site of the enzyme, and irreversible inhibition, where the inhibitor forms a stable complex with the enzyme, leading to a permanent reduction in enzyme activity.

Inhibition of DAGLβ results in decreased levels of 2-AG, which can have various effects on the endocannabinoid signaling pathways. For example, RHC 80267 is a well-known inhibitor that directly competes with diacylglycerol at the active site of DAGLβ. Orlistat, although primarily used to inhibit pancreatic lipases, can also nonspecifically inhibit DAGLβ. O-3841 and Compound 30 are selective for DAGLβ and reduce 2-AG levels by directly targeting the enzyme. CAY10566 and PF-04457845 represent irreversible inhibitors that covalently bind to DAGLβ, leading to a sustained decrease in 2-AG synthesis. BIA 10-2474 is a broad-spectrum lipase inhibitor that has been reported to inhibit DAGLβ among other enzymes. Selective inhibitors such as KT109, KT185, and LEI-106 are valuable tools in elucidating the role of DAGLβ and the endocannabinoid system